ZYME · Healthcare · $1.9B
$26.49-2.61%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
6/'26
3/'26 vs prev quarter
Among 327 Biotechnology peers
Quarterly Revenue Growth
“이번 분기 가장 큰 주목 포인트는 파트너사 Jazz와 BeiGene이 준비 중인 자니다타맙(zanidatamab)의 미국 FDA 승인 기대예요.”
In the company's words · 2026 1분기 earnings call